Vagus Nerve Stimulation (VNS) for Mental Health: How It Works, Effectiveness, and What to Expect

Vagus nerve stimulation (VNS) is a neuromodulation therapy that delivers mild electrical impulses to the vagus nerve — one of the longest and most important nerves in the body. The vagus nerve runs from the brainstem through the neck and into the chest and abdomen, serving as a major communication highway between the brain and the body's internal organs. Its name comes from the Latin word for "wandering," reflecting its extensive reach throughout the body.

In the context of mental health treatment, VNS works by sending carefully calibrated electrical signals along the vagus nerve to brain regions involved in mood regulation, including the locus coeruleus, the nucleus tractus solitarius, the amygdala, and the prefrontal cortex. These structures play central roles in emotional processing, stress responses, and the regulation of neurotransmitters such as serotonin, norepinephrine, and gamma-aminobutyric acid (GABA) — all of which are implicated in mood disorders.

VNS exists in two primary forms:

• Implanted VNS (iVNS): A small pulse generator — roughly the size of a silver dollar — is surgically implanted under the skin in the left chest area. A thin wire connects the device to the left vagus nerve in the neck. The device delivers electrical pulses at programmed intervals, typically running for 30 seconds every five minutes, around the clock.
• Transcutaneous VNS (tVNS): A non-invasive alternative that delivers electrical stimulation through the skin, usually via a clip-on device placed on the ear (targeting the auricular branch of the vagus nerve) or a handheld device applied to the neck. These devices do not require surgery and are used for set periods each day.

The U.S. Food and Drug Administration (FDA) first approved implanted VNS for treatment-resistant epilepsy in 1997 and later approved it for treatment-resistant depression (TRD) in 2005. Transcutaneous VNS devices have received FDA clearance for certain conditions, including migraine and cluster headache, with research ongoing for psychiatric applications.

The mechanism by which VNS influences mood and mental health is complex and still an active area of research. However, several well-supported pathways have been identified:

• Neurotransmitter modulation: VNS increases the firing rate of neurons in the locus coeruleus and dorsal raphe nucleus, which are the brain's primary sources of norepinephrine and serotonin, respectively. Deficits in these neurotransmitter systems are strongly associated with major depressive disorder. Functional imaging studies show that VNS produces changes in these systems similar to — though mechanistically distinct from — those produced by antidepressant medications.
• Anti-inflammatory effects: The vagus nerve is a critical component of the cholinergic anti-inflammatory pathway. Stimulating it reduces the production of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6). This is clinically significant because chronic low-grade inflammation has been consistently linked to depression, and elevated inflammatory markers are found in a substantial proportion of individuals with treatment-resistant depression.
• Neuroplasticity: Research suggests that VNS promotes the expression of brain-derived neurotrophic factor (BDNF), a protein essential for neuronal growth, survival, and synaptic plasticity. Reduced BDNF levels have been observed in individuals with depression, and restoring BDNF-mediated neuroplasticity is thought to be one mechanism by which several antidepressant treatments work.
• Autonomic nervous system regulation: The vagus nerve is the primary nerve of the parasympathetic ("rest and digest") nervous system. VNS helps restore the balance between sympathetic ("fight or flight") and parasympathetic activity, which is often disrupted in mood and anxiety disorders. Improved heart rate variability (HRV) — a marker of healthy vagal tone — has been observed following VNS treatment.
• Altered brain network connectivity: Functional neuroimaging studies demonstrate that VNS modifies activity in the default mode network and limbic circuitry, brain networks consistently found to be dysregulated in depression and related conditions.

It is important to understand that these effects develop gradually. Unlike electroconvulsive therapy (ECT), which can produce rapid improvements, VNS typically requires weeks to months of continuous stimulation before meaningful mood changes are observed. This gradual onset is consistent with the slow neuroplastic and neurochemical changes the treatment induces.

VNS has its strongest evidence base and regulatory approval for the following conditions:

Treatment-Resistant Depression (TRD)

The FDA approved implanted VNS as an adjunctive (add-on) long-term treatment for chronic or recurrent major depressive disorder in adults who have not responded adequately to at least four antidepressant treatments. Treatment-resistant depression is generally defined as failure to achieve adequate response after two or more adequate trials of antidepressant therapy, though the FDA-approved VNS indication specifies a higher threshold of treatment resistance.

According to the DSM-5-TR, major depressive disorder is characterized by persistent depressed mood or loss of interest/pleasure, along with associated symptoms such as sleep disturbance, appetite changes, fatigue, difficulty concentrating, and feelings of worthlessness. When these episodes fail to respond to standard pharmacotherapy and psychotherapy, VNS becomes a viable consideration.

Treatment-Resistant Epilepsy

VNS was first developed for epilepsy that does not respond to anticonvulsant medications. While this is a neurological rather than psychiatric indication, it is worth noting because many individuals with epilepsy experience comorbid depression, and clinicians observed mood improvements in epilepsy patients receiving VNS — observations that prompted research into its antidepressant effects.

Emerging and Investigational Applications

Active research is exploring VNS — particularly the non-invasive transcutaneous form — for several other conditions:

• Post-traumatic stress disorder (PTSD): Preliminary studies suggest VNS may reduce hyperarousal symptoms and fear responses by modulating amygdala activity and promoting extinction of fear memories.
• Anxiety disorders: Given the role of vagal tone in autonomic regulation and the stress response, tVNS is being investigated for generalized anxiety disorder and panic disorder.
• Bipolar depression: Some open-label studies have examined VNS for depressive episodes in bipolar disorder, though evidence remains limited.
• Substance use disorders: Early research has explored whether VNS can reduce cravings and withdrawal symptoms by modulating reward circuitry.
• Cognitive enhancement and neuroinflammation: Research is ongoing into whether VNS can improve cognitive function in conditions characterized by neuroinflammation, including traumatic brain injury and some neurodegenerative disorders.

It is essential to emphasize that for most of these emerging applications, VNS remains investigational and is not yet approved. Individuals interested in VNS for conditions other than treatment-resistant depression or epilepsy should inquire about clinical trials.

Before Treatment: Evaluation and Candidacy

VNS is not a first-line treatment. Before being considered for implanted VNS, individuals typically undergo a comprehensive psychiatric evaluation confirming a diagnosis of treatment-resistant depression. This evaluation documents the history of treatment trials — including medications, psychotherapy, and often other interventions such as ECT or transcranial magnetic stimulation (TMS) — and their outcomes. A thorough medical evaluation ensures there are no surgical contraindications.

The Implantation Procedure

For implanted VNS, the surgery is typically performed on an outpatient basis under general anesthesia and takes approximately one to two hours. The surgeon makes two small incisions: one in the left side of the chest (where the pulse generator is placed) and one in the left side of the neck (where the lead wire is attached to the vagus nerve). Most individuals go home the same day or the following day.

The device is usually not activated for approximately two weeks after surgery, allowing the surgical site to heal. Activation and initial programming are performed in the clinician's office.

Ongoing Treatment and Programming

Once activated, the VNS device delivers stimulation automatically according to programmed parameters. Typical settings include:

• Stimulation on-time: 30 seconds
• Stimulation off-time: 5 minutes
• Frequency: 20–30 Hz
• Current intensity: 0.25–3.5 milliamps, gradually titrated upward

Clinicians adjust these parameters over time during office visits, typically every few weeks initially and then every few months. The goal is to find the optimal combination of settings that produces therapeutic benefit with tolerable side effects. Many newer VNS devices also allow patients to deliver additional on-demand stimulation by swiping a magnet over the generator.

The battery in the pulse generator lasts approximately 3–8 years depending on stimulation settings, after which a minor surgical procedure replaces the generator (the lead wire is usually left in place).

For Transcutaneous VNS (tVNS)

Non-invasive tVNS requires no surgery. The individual typically uses the device for set periods — commonly 15–60 minutes, one to three times daily — applying it to the ear or neck. Stimulation intensity is adjusted to a level that produces a tingling sensation without pain. Consistency of use is critical; benefits are unlikely to emerge without regular, sustained application.

Timeline for Results

Response to VNS is characteristically gradual. Research consistently shows that while some individuals notice subtle improvements within the first few months, clinically meaningful improvement often develops over 6 to 12 months and may continue to increase over two or more years of treatment. This slow trajectory distinguishes VNS from faster-acting interventions and requires patience and ongoing communication between the individual and their treatment team.

The evidence base for VNS in treatment-resistant depression has evolved significantly since early trials, though it remains a topic of active investigation and some scientific debate.

Key Clinical Evidence

The pivotal short-term randomized controlled trial (the D-02 study) comparing active VNS to sham stimulation over 10 weeks did not demonstrate a statistically significant difference, which complicated the FDA approval process. However, longer-term open-label data told a different story. The D-21 study — a large, long-term, prospective, observational study — followed individuals with treatment-resistant depression over five years, comparing those receiving VNS plus treatment-as-usual (TAU) to a matched group receiving TAU alone:

• At one year, response rates (defined as a 50% or greater reduction in depression severity scores) were approximately 27% in the VNS group compared to 13% in the TAU-only group.
• At five years, cumulative response rates reached approximately 68% for VNS plus TAU compared to 41% for TAU alone.
• Remission rates (meaning symptoms dropped below the clinical threshold) were also significantly higher in the VNS group over the long term.
• The VNS group showed lower rates of suicidal ideation and suicide attempts compared to the TAU-only group, a finding of considerable clinical importance given the high suicide risk in treatment-resistant depression.

These long-term findings are consistent with the understanding that VNS works through slow neuroplastic mechanisms. The disconnect between the negative short-term randomized trial and the strongly positive long-term data has been a subject of ongoing methodological discussion in the field.

Interpretation and Limitations

Several important caveats apply to this evidence:

• The long-term studies are primarily open-label and observational, meaning participants and clinicians knew who was receiving VNS. This introduces potential bias, including placebo effects and differences in clinical attention.
• The lack of a positive short-term randomized controlled trial means the evidence does not meet the gold standard typically required for treatment validation, though some researchers argue that the standard 10-week RCT design is poorly suited to evaluating a treatment that requires months to years to demonstrate full effect.
• Selection bias may affect observational comparisons — individuals who opt for and maintain VNS implants may differ from those who decline in ways that influence outcomes.

Evidence for Transcutaneous VNS

The evidence base for non-invasive tVNS in depression is less mature than for implanted VNS. Several small randomized controlled trials have shown promising results for tVNS in reducing depressive symptoms, but study sizes are generally small and follow-up periods short. A 2022 systematic review and meta-analysis found that tVNS produced modest but statistically significant reductions in depressive symptoms compared to sham stimulation. However, the clinical significance of these reductions — and whether they translate to meaningful improvement in daily functioning — requires further investigation in larger, longer trials.

Despite these limitations, the overall trajectory of VNS research points toward genuine and clinically meaningful long-term antidepressant effects, particularly for individuals with severe, chronic, treatment-resistant depression for whom other options have been exhausted.

Common Side Effects of Implanted VNS

The most frequently reported side effects of implanted VNS are related to the electrical stimulation of the vagus nerve and surrounding tissues, and many diminish over time or with adjustment of stimulation parameters:

• Voice alteration or hoarseness: This is the most common side effect, reported by roughly 50–60% of individuals, particularly during stimulation cycles. It occurs because the recurrent laryngeal nerve, which controls the vocal cords, runs adjacent to the vagus nerve.
• Cough: Reported by approximately 20–30% of individuals.
• Throat pain or tingling: A sensation of tightness or vibration in the throat during stimulation.
• Shortness of breath: Mild dyspnea during stimulation periods is occasionally reported.
• Headache and neck pain: Particularly in the weeks following implantation.
• Difficulty swallowing (dysphagia): Usually mild and often limited to stimulation-on periods.

Surgical Risks

As with any surgical procedure, VNS implantation carries risks including:

• Infection at the incision site (reported in approximately 3–6% of cases)
• Vocal cord paralysis (rare, occurring in fewer than 1% of cases)
• Damage to surrounding nerves or blood vessels
• Pain at the implantation site
• Device malfunction or lead fracture, potentially requiring reoperation

Side Effects of Transcutaneous VNS

Non-invasive tVNS has a more favorable side effect profile. Commonly reported effects include mild skin irritation at the stimulation site, tingling, headache, and occasional dizziness. Serious adverse events are rare.

Important Limitations

• VNS does not work for everyone. Even in long-term studies, approximately one-third of individuals with treatment-resistant depression did not achieve a clinically meaningful response. Predicting who will respond remains difficult, and there are currently no reliable biomarkers to guide patient selection.
• The slow onset of action requires sustained commitment and can be discouraging for individuals who are severely depressed and hoping for rapid relief.
• VNS is an adjunctive treatment. It is designed to be used alongside medications and psychotherapy, not as a standalone intervention. Continuing other treatments is essential.
• MRI compatibility is limited with implanted VNS. While newer devices are conditionally MRI-compatible, there are restrictions on the type and settings of MRI scans that can be performed safely, which can complicate future medical care.
• VNS cannot be easily discontinued. Removing the implant requires surgery. While the device can be turned off, the hardware remains in the body unless surgically explanted.

Accessibility is one of the most significant barriers to VNS treatment, and understanding the financial landscape is essential for informed decision-making.

Cost of Implanted VNS

The total cost of VNS implantation — including the device, surgery, and initial programming — typically ranges from $20,000 to $40,000 or more in the United States. Ongoing costs include office visits for device programming, battery replacement surgery every several years, and continued psychiatric care.

Insurance Coverage

Insurance coverage for VNS in depression is inconsistent. Although VNS received FDA approval for treatment-resistant depression in 2005, the Centers for Medicare and Medicaid Services (CMS) issued a non-coverage determination in 2007, concluding at that time that the evidence was insufficient for Medicare coverage. This decision has not been formally reversed, though coverage reviews are ongoing and may change as newer evidence accumulates. Private insurers vary in their coverage policies — some cover VNS for depression while many do not, or require extensive prior authorization demonstrating treatment resistance.

By contrast, VNS for epilepsy is broadly covered by most insurance plans and Medicare.

Transcutaneous VNS Costs

Non-invasive tVNS devices are substantially less expensive, though costs vary. The gammaCore device (FDA-cleared for headache disorders) costs approximately $600 per month, and insurance coverage depends on the specific indication. Auricular tVNS devices marketed as wellness products are available at lower price points, but these are generally not FDA-cleared for psychiatric treatment and vary widely in quality and reliability.

Geographic Accessibility

VNS implantation is typically performed at academic medical centers or specialized neurosurgery practices. This concentrates access in urban areas and can create significant travel burdens for individuals in rural or underserved communities. The need for ongoing in-person programming visits adds to this challenge, though some newer devices allow limited remote monitoring and adjustment.

Navigating the System

Individuals considering VNS should:

• Request a detailed cost estimate from the implanting center, including the device, surgery, anesthesia, and programming visits.
• Contact their insurance provider early in the process to determine coverage and appeal options.
• Ask about patient assistance programs offered by device manufacturers (LivaNova, the manufacturer of the FDA-approved VNS Therapy system, has historically offered financial assistance programs).
• Inquire about clinical trials, which may provide the treatment at no cost to the participant.

Finding a qualified VNS provider requires some research, as not all psychiatrists or neurologists offer this treatment. Here are practical steps:

• Start with your current psychiatrist. If you have a psychiatrist managing your treatment-resistant depression, they can evaluate whether VNS is appropriate and provide a referral. Even if they do not implant devices, they can coordinate with a VNS center.
• Contact academic medical centers. University-affiliated hospitals with departments of psychiatry and neurosurgery are the most common settings for VNS implantation. Many have dedicated neuromodulation programs that offer VNS, TMS, ECT, and other brain stimulation therapies.
• Use the manufacturer's provider locator. LivaNova, the maker of the FDA-approved VNS Therapy system, maintains a provider locator tool on their website that can help identify implanting centers in your area.
• Search ClinicalTrials.gov. If VNS is not accessible through standard clinical channels — or if you are interested in VNS for a condition where it remains investigational — searching for active clinical trials at ClinicalTrials.gov is a valuable step. Trials may offer VNS at no cost and provide access to the latest devices and protocols.
• Seek a second opinion. Given the complexity of treatment-resistant depression and the significance of surgical implantation, obtaining a second opinion from a psychiatrist specializing in neuromodulation is reasonable and often encouraged.

When evaluating a provider, consider asking:

• How many VNS implantations have they performed?
• What is their protocol for programming and follow-up?
• What outcomes have their patients typically experienced?
• What other neuromodulation options do they offer, and how do they make treatment recommendations?

VNS is one of several neuromodulation and advanced treatment options available for treatment-resistant depression. Understanding the alternatives is important for making an informed decision in collaboration with your treatment team.

Transcranial Magnetic Stimulation (TMS)

TMS uses magnetic pulses to stimulate specific brain regions — most commonly the left dorsolateral prefrontal cortex. It is non-invasive, does not require anesthesia, and is FDA-cleared for treatment-resistant depression (with a lower threshold of treatment resistance than VNS — typically failure of one adequate antidepressant trial). A standard course involves daily sessions over four to six weeks. Response rates in clinical trials are approximately 50–60%, with remission rates around 30%. TMS is more widely available and better covered by insurance than VNS, making it a common next step before considering VNS.

Electroconvulsive Therapy (ECT)

ECT remains the most effective acute treatment for severe, treatment-resistant depression, with response rates of approximately 50–70%. It involves brief electrical stimulation of the brain under general anesthesia to induce a controlled seizure. ECT works more rapidly than VNS (often within 2–4 weeks) but requires repeated treatments and carries side effects including temporary cognitive disturbance and memory issues. It is often used as an acute intervention, with VNS or other strategies considered for long-term maintenance.

Ketamine and Esketamine

Ketamine, an NMDA receptor antagonist, has demonstrated rapid antidepressant effects — often within hours. Esketamine (Spravato), a nasal spray formulation, received FDA approval for treatment-resistant depression in 2019. These treatments can provide rapid relief but typically require repeated dosing and ongoing administration. They are often used alongside traditional antidepressants and psychotherapy.

Deep Brain Stimulation (DBS)

DBS involves surgically implanting electrodes deep within specific brain regions (such as the subcallosal cingulate cortex or ventral capsule/ventral striatum). It remains investigational for depression and is available only through clinical trials. DBS carries greater surgical risk than VNS but is being studied for the most severe, refractory cases.

Psychotherapy Intensification

Evidence-based psychotherapies — particularly cognitive behavioral therapy (CBT), behavioral activation, and interpersonal therapy (IPT) — remain important components of depression treatment even when pharmacotherapy has been inadequate. Intensive outpatient programs or structured therapy protocols may offer benefit as part of a comprehensive treatment plan.

Medication Optimization

Before pursuing neuromodulation, a thorough review of medication trials is essential. This includes evaluating whether adequate doses were tried for adequate durations, whether augmentation strategies (such as lithium, atypical antipsychotics, or thyroid hormone augmentation) have been explored, and whether pharmacogenomic testing might inform medication selection. A medication review by a psychopharmacology specialist can sometimes identify overlooked options.

If you or someone you know is living with depression that has not responded to multiple treatment attempts, it is important to know that additional options exist. Treatment resistance does not mean treatment is impossible — it means the right intervention has not yet been found.

Consider exploring VNS or other neuromodulation therapies if:

• You have been diagnosed with major depressive disorder and have not responded adequately to multiple antidepressant trials at appropriate doses and durations.
• You have tried psychotherapy and found it insufficient on its own.
• Your depression is chronic or recurrent and significantly impairs your daily functioning, relationships, or quality of life.
• You have discussed and possibly attempted other treatments such as TMS or ECT.

Important reminders:

• Only a qualified mental health professional can determine whether your symptoms and treatment history are consistent with a pattern that warrants consideration of VNS. Self-assessment alone is not sufficient.
• VNS is an adjunctive treatment — it works best as part of a comprehensive treatment plan that includes medication management, psychotherapy, and lifestyle interventions.
• If you are experiencing suicidal thoughts, please contact the 988 Suicide & Crisis Lifeline by calling or texting 988, or go to your nearest emergency department. VNS is a long-term strategy and is not appropriate for acute psychiatric emergencies.

the field of treatment-resistant depression is changing. Advances in neuromodulation — including VNS — offer genuine hope for individuals who have struggled to find relief through conventional treatments. A frank, informed discussion with a psychiatrist knowledgeable about these options is the best first step.